en
PRISM’s BIOMI revolutionizes medical testing, offering rapid, AI-driven diagnostics for blood, urine, and saliva
Project representative: Fabrice Cifuentes
Delving into the world of innovative healthcare, we can find a new startup, PRISM, in the landscape of medical testing. PRISM’s latest innovation, BIOMI, disrupts the norms, ushering a revolution in rapid diagnostic testing (RDT). Biological testing just became simplified — no longer confined to labs but easily accessible everywhere, anytime.
How does it work? BIOMI is a highly accurate system that reads rapid test strips for blood, urine, and saliva analysis. Meeting today’s demand for swift and reliable results, BIOMI promises consistent results within a few minutes. The technology, an amalgamation of AI, LLM, and Chat GPT 4, integrates smoothly in healthcare centers, making immediate results during initial consultations feasible.
BIOMI is a boon for healthcare professionals. Doctors, nurses, pharmacists, and medical practitioners can now conduct tests promptly on their patients without the need for outsourcing to diagnostic labs. This not only saves time but also enhances the efficiency of their workflow, a crucial aspect in healthcare.
PRISM’s BIOMI is accessibility, simplicity, reliability, and speed. It’s not just another piece of technology; it’s a catalyst for enhancing preventive healthcare and early disease detection.
While the market is populated with competitors like Abionic, Abbott, and Mini Vidas, PRISM carves its niche. BIOMI successfully negates competitors’ complications, such as lengthy result times and fewer comprehensive test panels. By transitioning from a captive to an open market, BIOMI’s brand-agnostic and universal solution simplifies healthcare testing.
PRISM, founded in 2020 by Frédéric LAVOREL, Philippe Guedon, Sébastien DURY, and Philippe MAUREL, has a strong track record. The team has developed five prototypes, each of which has undergone rigorous qualification and certification stages, ensuring the highest standards of quality and reliability.
A high level of global challenges can be noted in the future. User adaptability to new technologies and the accuracy of consistent results are paramount. Awareness campaigns and user acquisition strategies will continue to play a crucial role. Nevertheless, PRISM still makes a resounding impacts the healthcare sector, projecting sales of €100 million by 2028 and expanding connections globally.
